Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Harry M. Meade
Advertisement
Harry M. Meade, PhD, is senior vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Harry M. Meade
Advertisement
Latest Updated Articles
Production of Recombinant Therapeutic Proteins in the Milk of Transgenic AnimalsPublished: August 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Distribution Resilience: Meeting Global Demand and Delivering Faster, More Reliable Service
2
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
3
Streamlining Procurement and Inventory Management Leads to Increased Productivity
4
In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges
5
